Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.
Chaix
Marie-Laure
ML
Sahali
Sabrinel
S
Pallier
Coralie
C
Barrail-Tran
Aurélie
A
Delfraissy
Jean-François
JF
Ghosn
Jade
J
D000069454:Darunavir; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones; D019438:Ritonavir; D013449:Sulfonamides; D014779:Virus Replication / Q000187:drug effects*
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; D019438:Ritonavir; D000069454:Darunavir